Clinical trials
Lung Cancer (Locally Advanced or Metastatic) clinical trials
Below are recruiting lung cancer (locally advanced or metastatic) clinical trials, each written for real people, not researchers. We’re tracking 5,858 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05443087Recruiting
Checking blood levels of targeted drugs for digestive cancers
This trial monitors how your prescribed targeted cancer medicine moves through your body by doing extra blood tests. The goal is to understand the drug’s levels and dosing in people with advanced digestive cancers, so treatment can be better managed.
AmiensAges 18 years+ - NCT05501353Recruiting
Study tumor biomarkers in recurrent metastatic colon cancer
This study looks for blood/tumor signals (“biomarkers”) that may help predict outcomes in people whose colorectal cancer returns and spreads after surgery. It mainly helps researchers understand who may do better or worse, which can guide future care.
Hangzhou, ZhejiangAges 18–99 - NCT05525338RecruitingPhase 4
Test standard vs adjusted alectinib dose using blood levels
This trial compares the usual dose of alectinib with a modified dose chosen by checking alectinib blood levels. It aims to see whether adjusting the dose based on blood testing can work as well (and possibly be better tolerated) for people with ALK-positive non-small cell lung cancer.
Villejuif, Val-de-MarneAges 18 years+ - NCT05530759Recruiting
Testing blood and tumor samples for diagnostic cancer markers
This study looks at blood and tumor tissue to find signs (markers) that can help diagnose or better understand metastatic cancer. You may be able to join if you’re getting surgery or a biopsy to remove a tumor and there’s a safe way to collect samples.
Rochester, MinnesotaAges 18 years+ - NCT05534646RecruitingPhase 2
Apalutamide plus a cancer antibody for spreading prostate cancer
This Phase 2 study tests apalutamide combined with a targeted antibody (carotuximab) for prostate cancer that is still growing despite hormone treatment. It may help slow tumor growth by blocking cancer signals in different ways.
Duarte, CaliforniaAges 18 years+ - NCT05620628RecruitingPhase 2
Test savolitinib plus durvalumab for MET-amplified stomach cancer
This trial studies whether blocking MET (a cancer growth signal) with savolitinib, combined with durvalumab (an immune treatment), can shrink advanced gastric (stomach) cancer that has worsened after chemotherapy. It may help people whose tumors have MET amplification and measurable disease that can be tracked on scans.
SeoulAges 19 years+ - NCT05628038RecruitingPhase 2
Radiation plus immunotherapy for recurrent rectal cancer
This Phase 2 trial tests whether giving targeted radiation and an immunotherapy drug together can control locally recurring rectal cancer in the pelvis. It may help shrink tumors and slow disease growth, especially after certain prior treatments.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05655949RecruitingPhase 2
Y-90 radiation plus immunotherapy and chemo for bile duct cancer
This trial studies whether combining Y-90 liver radiation with an immunotherapy drug (durvalumab) and chemo (gemcitabine and cisplatin) can better control locally advanced or metastatic intrahepatic cholangiocarcinoma (bile duct cancer in the liver). It may help shrink tumors and slow disease growth, depending on how well the treatment works for your cancer type and overall health.
Boston, MassachusettsAges 18 years+ - NCT05663242RecruitingPhase 4
Comparing anesthetics for outcomes after lung tumor surgery
This study looks at whether using different anesthesia drugs during planned lung tumor surgery affects recovery and longer-term outcomes. It also aims to understand why the anesthesia choice might make a difference.
Kaohsiung CityAges 20–80 - NCT05665361RecruitingPhase 1/Phase 2
Testing palbociclib plus sasanlimab for advanced kidney cancers
This study tests a combination of two medicines—palbociclib and sasanlimab—in people with advanced clear cell or papillary kidney cancer. It’s mainly designed to check safety (and early signs of how well the treatment may work) in these cancer types.
Bethesda, MarylandAges 18–100 - NCT05673928RecruitingPhase 2
Tucatinib and T-DM1 for HER2-positive brain-metastasis tumors
This Phase 2 study tests tucatinib plus T-DM1 (ado-trastuzumab emtansine) in people with HER2-positive metastatic solid tumors that have spread to the brain. It aims to shrink brain and body tumors and help control cancer that is progressing in the brain.
Houston, TexasAges 18 years+ - NCT05700721RecruitingPhase 2
Niraparib and dostarlimab for cancer with growing brain spots
This trial studies whether the medicines niraparib and dostarlimab can slow advanced cancers that have active, growing brain metastases. It is meant for people whose brain tumors can be measured on MRI and who have had at least one previous treatment.
Houston, TexasAges 18 years+ - NCT05748834RecruitingPhase 2
Tucatinib plus Doxil for HER2-positive metastatic breast cancer
This Phase 2 study tests tucatinib (a HER2-targeted pill) plus Doxil (a chemotherapy medicine) to slow or shrink HER2-positive metastatic breast cancer that has been treated before. It may help by targeting HER2 cancer cells more effectively than past treatments alone.
Columbia, MarylandAges 18 years+ - NCT05753839Recruiting
Testing surgery plus immunotherapy for metastatic kidney cancer
This trial studies whether removing the kidney tumor (cytoreductive nephrectomy) before treatment can improve outcomes for people with metastatic clear-cell kidney cancer. All participants are expected to receive standard immunotherapy (nivolumab plus ipilimumab), and the study focuses on the role of surgery in the “immuno-oncology era.”
SeoulAges 18 years+ - NCT05770531RecruitingPhase 2
Blood test guides chemo changes for metastatic breast cancer
This Phase 2 study uses a blood test that looks for “circulating tumor DNA” to help decide if standard chemotherapy should be changed. It aims to see whether this approach improves how well treatment works for certain metastatic (stage IV) breast cancers.
Nashville, TennesseeAges 18 years+ - NCT05772390RecruitingPhase 2
Second radiation for a small breast cancer return
This Phase 2 study tests whether giving targeted radiation again to the same breast can control a small, local breast cancer that came back after prior whole-breast radiation. It may help some patients avoid or delay further treatment for the breast while carefully checking safety.
Meldola, Forlì CesenaAges 18 years+ - NCT05771181RecruitingPhase 2
Test vitamin E plus two cancer drugs for metastatic colon cancer
This trial tests whether adding vitamin E to two cancer medicines (fruityquintinib and tislelizumab) can work better in people with metastatic colorectal cancer that is mismatch-repair stable (MSS). It may help if your cancer has grown despite standard treatment, and you can meet the study’s safety and blood/organ requirements.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05784688RecruitingPhase 1/Phase 2
TU2218 with Keytruda for advanced solid tumors
This trial studies TU2218 taken with Keytruda (pembrolizumab) in adults with advanced solid cancers that have limited treatment options. The goal is to see if the combination can shrink tumors and is safe enough to keep using.
San Antonio, TexasAges 18 years+ - NCT05786716RecruitingPhase 2/Phase 3
Trastuzumab plus pertuzumab for HER2-mutated cancers
This trial tests whether combining trastuzumab and pertuzumab can treat cancers that have HER2 amplification or an activating HER2 mutation. It looks at people ages 12 and older, and may include both children/teens and adults, using the study drug based on their HER2 test results.
BelfastAges 12 years+ - NCT05795335Recruiting
Testing CDK4/6 medicines for advanced hormone-positive breast cancer
This trial studies how CDK4/6 medicines fit into treatment for people with advanced hormone receptor–positive breast cancer that cannot be cured with surgery or radiation. It may help doctors understand the best way to use these medicines for disease that has returned or spread.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05800275RecruitingPhase 2
Tucatinib and capecitabine plus spinal trastuzumab for HER2+ cancer
This Phase 2 trial tests a combination of tucatinib and capecitabine (taken by mouth) plus trastuzumab delivered into the spinal fluid, to treat breast cancer that has spread to the leptomeninges (lining around the brain/spinal cord). It may help reduce cancer activity in the spinal fluid and improve symptoms.
BordeauxAges 18 years+ - NCT05825456Recruiting
Study of surgery for broken bones from metastatic cancer
This trial looks at outcomes after surgery to stabilize a broken bone caused by cancer that has spread (metastatic cancer). It may help by improving how doctors plan and measure results after specific types of bone stabilization surgery.
Ankara, altindagAges Any age - NCT05827796RecruitingPhase 1/Phase 2
Testing IN10018 plus chemo with an added antibody in pancreatic cancer
This Phase 1/2 trial tests a new medicine (IN10018) and a specific added antibody (KN046) together with standard chemotherapy for advanced pancreatic cancer. It aims to see whether this combination can better control the cancer and how safely it can be given.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05832827RecruitingPhase 2
First treatment combo for thymic cancer using pembrolizumab plus drugs
This Phase 2 study tests a first (initial) treatment combination of pembrolizumab with three other drugs (carboplatin, paclitaxel, and lenvatinib) for advanced or recurrent thymic carcinoma. It aims to shrink tumors and improve control of the cancer when standard chemotherapy has not yet been tried for your situation.
Chūō, TokyoAges 18 years+
Hear when a new Lung Cancer (Locally Advanced or Metastatic) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer (locally advanced or metastatic)?
- Yes. Clin2 currently lists 5,858 recruiting lung cancer (locally advanced or metastatic) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer (locally advanced or metastatic) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer (locally advanced or metastatic) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced Non-Small Cell Lung Cancer
- Advanced or Metastatic Non-small Cell Lung Cancer
- Colorectal Cancer (Locally Advanced or Metastatic)
- Liver Cancer (Locally Advanced or Metastatic)
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.